| Dr Nelli Fromer, DO | |
|
374 Stockholm Street, Wyckoff Heights Medical Center, Brooklyn, NY 11237 | |
| (718) 302-8548 | |
| Not Available |
| Full Name | Dr Nelli Fromer |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 16 Years |
| Location | 374 Stockholm Street, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851551352 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 273127 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wyckoff Heights Medical Center | Brooklyn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wyckoff Professional Medical Services Pc | 6406748607 | 145 |
News Archive
Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.
Human rights violations - including murders, sexual assaults, and kidnapping - were common in Port-au-Prince, Haiti's capital city, after the departure of the democratically elected President in 2004, according to an Online/Article published by The Lancet.
Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
Among patients with severe trauma and major bleeding, those who received a transfusion of a balanced ratio of plasma, platelets, and red blood cells (RBCs) were more likely to have their bleeding stopped and less likely to die due to loss of blood by 24 hours compared to patients who received a transfusion with a higher ratio of RBCs, according to a study in the February 3 issue of JAMA.
In this post in IntraHealth International's "Global Health" blog, Editorial Manager Susanna Smith responds to an editorial published in the Lancet earlier this month that "issued a dire warning to the international medical community" about the use of medicine as a weapon of war in Syria, writing, "It is just the latest in a series of reports from across the Middle East on how medical care and medical professionals and facilities are being used to inflict politically motivated violence."
› Verified 4 days ago
| Entity Name | Wyckoff Professional Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659710796 PECOS PAC ID: 6406748607 Enrollment ID: O20040324001805 |
News Archive
Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.
Human rights violations - including murders, sexual assaults, and kidnapping - were common in Port-au-Prince, Haiti's capital city, after the departure of the democratically elected President in 2004, according to an Online/Article published by The Lancet.
Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
Among patients with severe trauma and major bleeding, those who received a transfusion of a balanced ratio of plasma, platelets, and red blood cells (RBCs) were more likely to have their bleeding stopped and less likely to die due to loss of blood by 24 hours compared to patients who received a transfusion with a higher ratio of RBCs, according to a study in the February 3 issue of JAMA.
In this post in IntraHealth International's "Global Health" blog, Editorial Manager Susanna Smith responds to an editorial published in the Lancet earlier this month that "issued a dire warning to the international medical community" about the use of medicine as a weapon of war in Syria, writing, "It is just the latest in a series of reports from across the Middle East on how medical care and medical professionals and facilities are being used to inflict politically motivated violence."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nelli Fromer, DO 840 45th St, Brooklyn, NY 11220-1611 Ph: () - | Dr Nelli Fromer, DO 374 Stockholm Street, Wyckoff Heights Medical Center, Brooklyn, NY 11237 Ph: (718) 302-8548 |
News Archive
Sorrento Therapeutics, Inc. announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have entered into a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California.
Human rights violations - including murders, sexual assaults, and kidnapping - were common in Port-au-Prince, Haiti's capital city, after the departure of the democratically elected President in 2004, according to an Online/Article published by The Lancet.
Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
Among patients with severe trauma and major bleeding, those who received a transfusion of a balanced ratio of plasma, platelets, and red blood cells (RBCs) were more likely to have their bleeding stopped and less likely to die due to loss of blood by 24 hours compared to patients who received a transfusion with a higher ratio of RBCs, according to a study in the February 3 issue of JAMA.
In this post in IntraHealth International's "Global Health" blog, Editorial Manager Susanna Smith responds to an editorial published in the Lancet earlier this month that "issued a dire warning to the international medical community" about the use of medicine as a weapon of war in Syria, writing, "It is just the latest in a series of reports from across the Middle East on how medical care and medical professionals and facilities are being used to inflict politically motivated violence."
› Verified 4 days ago
Dr. Alexander Usorov, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Hematology & Oncology Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |